Wealthfront Advisers’s Viking Therapeutics VKTX Stock Holding History
Bought
Maintained
Sold
Other funds holding VKTX
Wealthfront Advisers's VKTX Position: Q3 2026 in Review
Wealthfront Advisers reduced its Viking Therapeutics (VKTX) stake by 10% in Q3 2026, selling an estimated $39.1K and leaving 9,692 shares worth $316K. The position accounts for ﹤0.01% of the portfolio, ranked #967.
Wealthfront Advisers first reported a position in VKTX in Q4 2024 and has held it in 8 quarters since. The position peaked at $433K in Q4 2025. 443 funds tracked by Wall St. Rank hold VKTX as of Q3 2026.
- Wealthfront Advisers held 9,692 shares of Viking Therapeutics worth $316K as of Q3 2026.
- Wealthfront Advisers sold 1,130 Viking Therapeutics shares in Q3 2026, an estimated $39.1K.
- Viking Therapeutics made up ﹤0.01% of Wealthfront Advisers's portfolio in Q3 2026, its #967 holding.
- Wealthfront Advisers first reported a position in Viking Therapeutics in Q4 2024 and has held it in 8 quarters since.
- Wealthfront Advisers's Viking Therapeutics position peaked at $433K in Q4 2025.
- 443 funds tracked by Wall St. Rank held Viking Therapeutics as of Q3 2026.
Based on Wealthfront Advisers's 13F filing for Q3 2026, filed 9 Nov 2026.